PL1748781T3 - Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów - Google Patents

Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów

Info

Publication number
PL1748781T3
PL1748781T3 PL05765950T PL05765950T PL1748781T3 PL 1748781 T3 PL1748781 T3 PL 1748781T3 PL 05765950 T PL05765950 T PL 05765950T PL 05765950 T PL05765950 T PL 05765950T PL 1748781 T3 PL1748781 T3 PL 1748781T3
Authority
PL
Poland
Prior art keywords
methods
sulfated polysaccharides
bleeding disorders
treating bleeding
treating
Prior art date
Application number
PL05765950T
Other languages
English (en)
Inventor
Kirk W Johnson
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of PL1748781T3 publication Critical patent/PL1748781T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05765950T 2004-05-27 2005-05-27 Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów PL1748781T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57484504P 2004-05-27 2004-05-27
EP05765950A EP1748781B1 (en) 2004-05-27 2005-05-27 Methods for treating bleeding disorders using sulfated polysaccharides
PCT/US2005/018669 WO2005117912A1 (en) 2004-05-27 2005-05-27 Methods for treating bleeding disorders using sulfated polysaccharides

Publications (1)

Publication Number Publication Date
PL1748781T3 true PL1748781T3 (pl) 2013-05-31

Family

ID=35462725

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05765950T PL1748781T3 (pl) 2004-05-27 2005-05-27 Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów

Country Status (15)

Country Link
US (4) US7767654B2 (pl)
EP (2) EP2165711B1 (pl)
JP (2) JP5232470B2 (pl)
CN (2) CN103251647A (pl)
AU (1) AU2005249465B2 (pl)
BR (1) BRPI0511603A (pl)
CA (1) CA2567495C (pl)
CY (1) CY1113705T1 (pl)
DK (1) DK1748781T3 (pl)
ES (2) ES2482105T3 (pl)
PL (1) PL1748781T3 (pl)
PT (1) PT1748781E (pl)
RU (1) RU2347574C2 (pl)
SI (1) SI1748781T1 (pl)
WO (1) WO2005117912A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP2165711B1 (en) * 2004-05-27 2014-05-21 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
WO2007127298A2 (en) * 2006-04-27 2007-11-08 Avigen, Inc. Pucoidans for reducing blood coagulation
JP5679663B2 (ja) * 2007-02-23 2015-03-04 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 海藻抽出物からのフコイダン精製のためのプロセスの方法
US9956272B2 (en) * 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
JP5896742B2 (ja) * 2008-08-22 2016-03-30 バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA 出血性障害を処置するための方法
TWI488662B (zh) * 2008-12-11 2015-06-21 Baxter Int 基於血纖維蛋白元與硫酸化多醣的製劑
EP2379096B1 (en) 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
WO2011088267A1 (en) * 2010-01-14 2011-07-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
CA2796729C (en) * 2010-04-20 2020-06-23 Octapharma Ag Melezitose for stabilizing human blood plasma proteins
DK2624859T3 (en) 2010-10-06 2017-06-06 Medimmune Ltd FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY
EP2734213B1 (en) * 2011-07-19 2018-06-06 Baxalta GmbH Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
AU2013215167B2 (en) * 2012-01-30 2017-12-21 Baxalta GmbH Non-anticoagulant sulfated or sulfonated synthetic polymers
ES2699238T3 (es) 2012-01-30 2019-02-08 Baxalta GmbH Polisacáridos sulfatados o sulfonatados no anticoagulantes
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
RU2472495C1 (ru) * 2012-05-05 2013-01-20 Илья Николаевич Медведев Способ нормализации уровня альфа2-антиплазмина у свиноматок с бронхитом
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
CA2881785A1 (en) * 2012-08-14 2014-02-20 Baxter International Inc. Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
CN103610684B (zh) * 2013-11-07 2016-04-06 苏州大学 糖类在制备治疗血小板数量相关疾病的药物中的应用
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
JPWO2018043667A1 (ja) 2016-08-31 2018-08-30 王子ホールディングス株式会社 酸性キシロオリゴ糖の製造方法及び酸性キシロオリゴ糖
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
CN110678189A (zh) 2017-05-31 2020-01-10 王子控股株式会社 保湿外用剂
EP3683242B1 (en) 2017-09-12 2024-10-30 Oji Holdings Corporation Pentosan polysulfate and method for producing pentosan polysulfate
CA3086301C (en) 2017-12-20 2025-04-08 Oji Holdings Corporation PENTOSANNE POLYSULFATE AND MEDICINE CONTAINING PENTOSANNE POLYSULFATE
CN108822231A (zh) * 2018-06-29 2018-11-16 桂林理工大学 一种具有提高抗氧化活性的果胶多糖硫酸化修饰产物及其制备方法
SE1950885A1 (en) * 2019-07-11 2021-01-12 Faelker Knut Treatment of patients under antiplatelet medication experiencing acute bleeding complications during/after surgery

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79254A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
JP3094165B2 (ja) * 1990-11-05 2000-10-03 バクスター、ダイアグノスチックス、インコーポレイテッド 抗凝固剤濃度測定方法
JP3714426B2 (ja) 1994-02-01 2005-11-09 株式会社糖鎖工学研究所 フコイダンオリゴ糖組成物含有癌転移抑制剤
EP0870771B1 (en) * 1995-04-28 2008-11-12 Takara Bio Inc. Sugar compounds
FR2754183A1 (fr) * 1996-10-08 1998-04-10 Lefebvre Jean Marie Composition visqueuse hemostatique, notamment a l'etat de gel
ATE290215T1 (de) * 1997-04-25 2005-03-15 Pentapharm Ag Verfahren zum funktionellen nachweis von störungen im protein c-system
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
KR100727339B1 (ko) * 1999-04-15 2007-06-12 다카라 바이오 가부시키가이샤 치료제
WO2001074399A1 (en) * 2000-03-30 2001-10-11 Ajinomoto Co., Inc. Drugs retained in target tissue over long time
CA2437015A1 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
DE60202427T2 (de) * 2001-10-24 2005-12-29 Takara Bio Inc., Otsu Sulfatiertes Fucan-Oligosaccharid
JP3941036B2 (ja) 2001-12-07 2007-07-04 サンスター株式会社 経口投与のためのリポソーム組成物
DE10309368A1 (de) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase
IL152030A0 (en) * 2002-09-30 2003-05-29 Nvr Labs Ltd Neural & Vascular Cohesive biopolymers comprising sulfated polysaccharides and fibrillar proteins and use thereof for tissue repair
JP2004144580A (ja) * 2002-10-23 2004-05-20 Japan Clinical Laboratories Inc 血液凝固検査方法
EP1644416A4 (en) * 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
EP2165711B1 (en) * 2004-05-27 2014-05-21 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
WO2007127298A2 (en) * 2006-04-27 2007-11-08 Avigen, Inc. Pucoidans for reducing blood coagulation

Also Published As

Publication number Publication date
US20110237512A1 (en) 2011-09-29
PT1748781E (pt) 2013-01-22
AU2005249465A1 (en) 2005-12-15
CN103251647A (zh) 2013-08-21
HK1103624A1 (en) 2007-12-28
CA2567495A1 (en) 2005-12-15
ES2399277T3 (es) 2013-03-27
CY1113705T1 (el) 2016-06-22
JP2012046551A (ja) 2012-03-08
EP2165711A1 (en) 2010-03-24
RU2347574C2 (ru) 2009-02-27
CA2567495C (en) 2014-02-18
US7829549B2 (en) 2010-11-09
EP1748781A1 (en) 2007-02-07
EP1748781B1 (en) 2012-12-19
US7767654B2 (en) 2010-08-03
RU2006146801A (ru) 2008-07-10
US20120129777A1 (en) 2012-05-24
HK1142276A1 (en) 2010-12-03
CN1984664B (zh) 2013-07-24
US20090269325A1 (en) 2009-10-29
JP5232470B2 (ja) 2013-07-10
JP2008500367A (ja) 2008-01-10
EP2165711B1 (en) 2014-05-21
AU2005249465B2 (en) 2007-12-06
SI1748781T1 (sl) 2013-03-29
CN1984664A (zh) 2007-06-20
ES2482105T3 (es) 2014-08-01
DK1748781T3 (da) 2013-02-11
US20050282771A1 (en) 2005-12-22
US8771973B2 (en) 2014-07-08
BRPI0511603A (pt) 2008-01-02
EP1748781A4 (en) 2008-07-02
US8859526B2 (en) 2014-10-14
WO2005117912A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
SI1748781T1 (sl) Postopki za zdravljenje motenj krvavenja ob uporabi sulfatiranih polisaharidov
EP1855710A4 (en) MUSCLE REGENERATION
IL183985A0 (en) Methods for treating autoimmune disorders
IL186408A0 (en) Combination treatment methods
PL1805312T3 (pl) Sposoby i środki do wytwarzania hialuronianu
IL187450A0 (en) Methods for treating fibrotic conditions
IL182011A0 (en) Treatment screening methods
GB0526291D0 (en) Therapeutic method
ZA200705459B (en) Treatment method
EP1797020A4 (en) GUANIDINE POLYSACCHARIDES, THEIR USE AS ABSORBENTS AND PROCESS FOR THE PRODUCTION THEREOF
BRPI0506723A (pt) métodos para o tratamento de distúrbios vasculares
EP1912658A4 (en) THERAPEUTIC PROTOCOLS WITH HYALURONANE
GB0525957D0 (en) Methods
EP1883405A4 (en) METHODS OF TREATING NEPHROLITHIASIS
GB0516068D0 (en) Well treatment
GB0525540D0 (en) New treatment
GB0518232D0 (en) New methods
PT1686201E (pt) Aparelho de pulling-down
IL188127A0 (en) Methods for treating demyelination disorders
GB0715741D0 (en) Methods
GB0502171D0 (en) Well treatment
GB0518425D0 (en) Methods
EP1928498A4 (en) METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
ZA200709915B (en) Methods for treating fibrotic conditions
GB0514661D0 (en) Methods